Multi-omics approach to improve eye health in uveitis
Official title: Multi-omics Strategies to Improve Clinical Outcomes in Uveitis
Funded at University of California, San Francisco · NIH-11419671 · Data updated 2026-11-12
Aims to use advanced genetic and molecular testing to better diagnose and predict outcomes for people with uveitis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $512,721 |
| NIH project number | 5R01EY036058-03 |
| Project ID | NIH-11419671 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with uveitis or suspected infectious eye inflammation who could contribute samples or data.
✕Less likely to help
Patients without uveitis or infectious ocular disease may not benefit from this study.
What this research studies
If you have uveitis, this project would collect eye-related samples and use high-tech sequencing to find pathogens and host response patterns. Researchers will map which microbes are linked to different regions and seasons and see how these infections affect vision. They will also study your gene expression to identify markers that forecast recovery or progression, with collaboration from local and international partners. The goal is to classify uveitis more accurately and guide personalized treatment in the future.
Why it matters
Potential benefit: If successful, patients with uveitis could receive faster, more precise diagnoses and personalized treatment plans that protect vision.
How similar studies have gone: Prior work with metagenomic sequencing has improved infectious disease detection, but this project extends to uveitis with host-response profiling.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Doan, Thuy a — University of California, San Francisco
- Study coordinator: Doan, Thuy a
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.